Katherine Stueland

Directeur Général chez GENEDX HOLDINGS CORP. Fortune : 5 M $ au 31/05/2026

Profil

Currently, Katherine A. Stueland is Chief Executive Officer & Director at GeneDx Holdings Corp.
starting in 2026, President & Chief Executive Officer at GeneDx LLC since 2021, Director at Cancan Health, and President & Director at Sema4 OpCo, Inc. Formerly, Ms. Stueland was President & Chief Executive Officer at GeneDx, Inc., Director at Rivkin Center for Ovarian Cancer, VP-Corporate Communications & Investor Relations at Dendreon Corp.
from 2011 to 2012, Principal at Vivo Communications, LLC in 2013, and Chief Commercial Officer at Invitae Corp.
from 2016 to 2021.
Education includes an undergraduate degree from Miami University, conferred in 1997.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
GENEDX HOLDINGS CORP. CLASS A 0,36 %	16/06/2026	104 372 ( 0,36 % )	5 M $	31/05/2026

Postes actifs de Katherine Stueland

Sociétés	Poste	Début
GENEDX HOLDINGS CORP.	Directeur Général	29/04/2022
Cancan Health	Directeur/Membre du Conseil	-
GeneDx LLC	Directeur Général	01/06/2021
Mount Sinai Genomics, Inc.	President	-

Anciens postes connus de Katherine Stueland

Sociétés	Poste	Fin
INVITAE CORPORATION	Investor Relations Contact	01/10/2016
Vivo Communications, LLC	Corporate Officer/Principal	01/12/2013
DENDREON CORPORATION	Investor Relations Contact	01/06/2012
GeneDx, Inc.	Directeur Général	-
Rivkin Center for Ovarian Cancer	Directeur/Membre du Conseil	-